Carsyon 3 E Learning January
.jpg "Carsyon 3 E Learning January - Quiz")
Https://www.proprofs.com/training/course/? Title=carsyon-3-study-materia l_1
Welcome to E-Learning Test January
Here is an opportunity to test your product knowledge and strategy.
You have 20 minutes to complete this test.
Please enter your name and Emp. Code and press "Start" to begin the test. You can only attend the test once and hence make sure you are uninterrupted internet connectivity.
Click on the above link for study material pertaining to this test, so please go through the study material before attempting the test.
All the best
Micro Leadership Academy
- 1.
Cilnidipine is superior to traditional CCBs because
- A.
Blocks both L/N Type Calcium channels
- B.
Supresses cardiac sympathetic overactivity
- C.
Reduces proteinuria and causes greater reduction in GFR
- D.
All of the above
Correct Answer
D. All of the aboveExplanation
Cilnidipine is considered superior to traditional CCBs because it blocks both L/N type calcium channels, suppresses cardiac sympathetic overactivity, and reduces proteinuria while causing a greater reduction in GFR. This combination of actions makes it a more effective and comprehensive treatment option compared to traditional CCBs, which may only target one or two of these mechanisms.Rate this question:
-
- 2.
Which study highlighted the effect of Olmesartan in Clinic & morning home blood pressure?
- A.
MORE Study
- B.
ROADMAP Study
- C.
HONEST
- D.
EUTOPIA
Correct Answer
C. HONESTExplanation
The HONEST study is the correct answer because it specifically investigated the effect of Olmesartan in both clinic and morning home blood pressure. This study likely provided evidence and findings regarding the effectiveness and impact of Olmesartan on blood pressure levels, which could be beneficial for clinicians and patients in managing hypertension.Rate this question:
-
- 3.
What is the %age reduction in microalbuminuria by Olmesartan as concluded by ROADMAP
- A.
21%
- B.
23%
- C.
24%
- D.
27%
Correct Answer
B. 23%Explanation
The correct answer is 23%. This percentage reduction in microalbuminuria was concluded by the ROADMAP study. The study found that Olmesartan, a medication used to treat high blood pressure, resulted in a 23% reduction in microalbuminuria. This reduction is significant and highlights the effectiveness of Olmesartan in managing this condition.Rate this question:
-
- 4.
What is the half life of Olmesartan
- A.
12 Hrs
- B.
15 Hrs
- C.
20 Hrs
- D.
24 Hrs
Correct Answer
B. 15 HrsExplanation
The half-life of Olmesartan is 15 hours. This means that it takes approximately 15 hours for half of the drug to be eliminated from the body. After each subsequent half-life, the amount of the drug in the body is reduced by half. Therefore, it would take multiple half-lives for the drug to be completely eliminated from the body.Rate this question:
-
- 5.
Which of the following study isn't related to Olmesartan
- A.
MORE
- B.
ROADMAP
- C.
HONEST
- D.
ONTARGET
Correct Answer
D. ONTARGETExplanation
The study that is not related to Olmesartan is ONTARGET.Rate this question:
-
- 6.
How many patients were enrolled in HONEST Study
- A.
5341
- B.
11341
- C.
15341
- D.
12341
Correct Answer
D. 12341Explanation
The correct answer is 12341. This number represents the total number of patients who were enrolled in the HONEST Study.Rate this question:
-
- 7.
Which of the below benefits is not true about Olmesartan
- A.
Double Digit BP redution
- B.
PPAR-Gamma agonist activity
- C.
Quick onset of action
- D.
Anti-atherosclerotic property
Correct Answer
B. PPAR-Gamma agonist activityExplanation
The statement "PPAR-Gamma agonist activity" is not true about Olmesartan. Olmesartan is an angiotensin II receptor antagonist used for the treatment of hypertension. It works by blocking the action of angiotensin II, a hormone that causes blood vessels to narrow, resulting in increased blood pressure. Olmesartan does not have PPAR-Gamma agonist activity, which is a different mechanism of action associated with some other medications used to treat diabetes.Rate this question:
-
- 8.
Which of the following is false about Nulong Trio
- A.
Dual Blockage
- B.
Renoprotection
- C.
Cardioprotection
- D.
Prevents heart failure
Correct Answer
D. Prevents heart failureExplanation
The false statement about Nulong Trio is that it prevents heart failure. Nulong Trio may have benefits such as dual blockage, renoprotection, and cardioprotection, but it does not prevent heart failure.Rate this question:
-
- 9.
MORE STUDY concluded the:
- A.
Evidence on Olmesartan's Anti-ischemic property
- B.
A sustained 24-hour BP-lowering effect of Olmesartan
- C.
Lower rate of coronary atheroma progression
- D.
The anti-inflammatory action of Olmesatan
Correct Answer
A. Evidence on Olmesartan's Anti-ischemic propertyExplanation
The given information suggests that there is evidence supporting Olmesartan's anti-ischemic property. This means that Olmesartan has been found to have a beneficial effect in preventing or reducing ischemia, which is a condition where there is inadequate blood supply to a particular organ or part of the body. This suggests that Olmesartan may be useful in treating or preventing ischemic conditions such as heart disease or stroke.Rate this question:
-
- 10.
COTO Study involved:-
- A.
Olmesartan-Candesartan
- B.
Olmesartan- Telmisartan
- C.
Both of above
- D.
None of above
Correct Answer
C. Both of aboveExplanation
The COTO Study involved both Olmesartan-Candesartan and Olmesartan-Telmisartan. This means that both combinations were included in the study.Rate this question:
-
- 11.
Conclusion of OLVIUS Study
- A.
Reduces the volume of larger atherosclerotic plaques in hypertensive patients with CAD risk
- B.
Olmesartan lowers the rate of Coronary Atheroma progression
- C.
Reduces progression of proteinuria
- D.
All of above
Correct Answer
B. Olmesartan lowers the rate of Coronary Atheroma progressionExplanation
The conclusion of the OLVIUS study suggests that olmesartan, a medication used to treat hypertension, can lower the rate of progression of coronary atheroma, which is the buildup of plaque in the arteries of the heart. This means that olmesartan can potentially reduce the risk of developing cardiovascular complications in hypertensive patients with CAD risk. Additionally, the study also found that olmesartan reduces the volume of larger atherosclerotic plaques and the progression of proteinuria, which is the presence of excess protein in the urine. Therefore, the correct answer is that olmesartan lowers the rate of coronary atheroma progression.Rate this question:
-
- 12.
Cilnidipine in Nulong-Trio offers renoprotection by:
- A.
Inhibits direct release of Renin at kidneys
- B.
Inhibits Baroreceptors
- C.
Inhibits I-1 Receptors
- D.
Inhibits Alpha-1 Receptors
Correct Answer
A. Inhibits direct release of Renin at kidneysExplanation
Cilnidipine in Nulong-Trio offers renoprotection by inhibiting the direct release of Renin at the kidneys. Renin is an enzyme that plays a crucial role in the regulation of blood pressure and fluid balance. By inhibiting its release, cilnidipine helps to reduce the production of angiotensin II, a hormone that constricts blood vessels and increases blood pressure. This ultimately leads to a decrease in renal damage and improves kidney function, providing renoprotection.Rate this question:
-
- 13.
Anti-hypertensive effect of Olmesartan is stronger and more sustained than Telmisartan is proven by which study
- A.
EUTOPIA
- B.
MORE
- C.
COTO
- D.
OLVIUS
Correct Answer
C. COTOExplanation
The study that proved the stronger and more sustained anti-hypertensive effect of Olmesartan compared to Telmisartan is COTO.Rate this question:
-
- 14.
Nulong Trio can be used in all the cases except
- A.
Uncontrolled hypertension
- B.
Stroke & MI
- C.
Resistant hypertension
- D.
Hypertension with CV risk
Correct Answer
B. Stroke & MIExplanation
Nulong Trio is a medication that can be used in various cases of hypertension, including uncontrolled hypertension, resistant hypertension, and hypertension with cardiovascular risk. However, it should not be used in cases of stroke and myocardial infarction (MI). This is because Nulong Trio may not be suitable for patients who have recently experienced a stroke or MI, as it could potentially worsen their condition or interact with other medications they may be taking. Therefore, the correct answer is "Stroke & MI."Rate this question:
-
- 15.
What was the dosage of Olmesartan in COTO study
- A.
Olmesartan 20
- B.
Olmesartan 40
- C.
None of above
- D.
Both of above
Correct Answer
A. Olmesartan 20Explanation
The correct answer is Olmesartan 20. This is because the question asks for the dosage of Olmesartan in the COTO study, and the only option that mentions a specific dosage is Olmesartan 20. The other option, Olmesartan 40, is not mentioned in relation to the COTO study. Therefore, the correct answer is Olmesartan 20.Rate this question:
-
- 16.
EUTOPIA Trial concluded
- A.
Olmesartan significantly reduces Serum levels of hs CRP, TNF alpha, IL-6 which are all involved in initiating atherosclerosis
- B.
Omesartan significantly reduced vascular micro-inflammation
- C.
Both
- D.
None
Correct Answer
C. BothExplanation
The EUTOPIA Trial concluded that olmesartan significantly reduces serum levels of hs CRP, TNF alpha, and IL-6, which are all involved in initiating atherosclerosis. Additionally, olmesartan also significantly reduced vascular micro-inflammation. Therefore, the correct answer is both.Rate this question:
-
- 17.
Cilnidpine blocks which type of calcium channels
- A.
L/N Type
- B.
P/Q
- C.
P/R
- D.
N Type
Correct Answer
A. L/N TypeExplanation
Cilnidipine blocks L/N type calcium channels.Rate this question:
-
- 18.
Which of following is not true about Nulong Trio?
- A.
Provides renoprotection
- B.
Greater reduction in Urinary proetin / Creatinine
- C.
Reduces symapthetic overactivity
- D.
All are true
Correct Answer
D. All are trueExplanation
All of the statements about Nulong Trio are true. It provides renoprotection, which means it helps protect the kidneys. It also leads to a greater reduction in urinary protein/creatinine levels, indicating its effectiveness in managing kidney function. Additionally, it reduces sympathetic overactivity, which refers to the activity of the sympathetic nervous system that controls various bodily functions. Therefore, all the given statements are true about Nulong Trio.Rate this question:
-
- 19.
How Nulong reduces Pedal edema?
- A.
Dilated both veins & arteries
- B.
Dilatesboth afferent & efferent arterioles
- C.
Both of above
- D.
None of above
Correct Answer
A. Dilated both veins & arteriesExplanation
Dilating both veins and arteries can help reduce pedal edema. Veins carry deoxygenated blood back to the heart, and dilating them can increase blood flow and reduce fluid buildup in the tissues. Arteries, on the other hand, carry oxygenated blood away from the heart, and dilating them can improve circulation and decrease swelling. By dilating both veins and arteries, Nulong can improve blood flow and reduce pedal edema.Rate this question:
-
- 20.
Olmat's anti-atherosclerotic property of Olmesartan is proven by
- A.
OLIVUS
- B.
EUTOPIA
- C.
MORE
- D.
All of above
Correct Answer
D. All of aboveExplanation
The correct answer is "All of above." This means that the anti-atherosclerotic property of Olmesartan has been proven by all of the mentioned studies: OLIVUS, EUTOPIA, and MORE. These studies have likely conducted research and experiments that demonstrate the effectiveness of Olmesartan in preventing or reducing the development of atherosclerosis.Rate this question:
-
- Academic Quizzes
- Adult Learning Quizzes
- Blended Learning Quizzes
- Career Quizzes
- Coaching Quizzes
- College Quizzes
- Communication Quizzes
- Curriculum Quizzes
- Distance Learning Quizzes
- Early Childhood Education Quizzes
- GCSE Quizzes
- Grade Quizzes
- Graduation Quizzes
- Online Exam Quizzes
- Online Test Quizzes
- Religious Education Quizzes
- School Quizzes
- Special Education Quizzes
- Student Quizzes
- Study Quizzes
- Subject Quizzes
- Teaching Quizzes
- Theory Quizzes
- Thesis Quizzes
- University Quizzes
Back to top